Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization

Journal of Cellular Biochemistry

Volumn 114, Issue 8, 2013, Pages 1901-1907

  Ota, Kuniaki ^a   Quint, Patrick ^a   Ruan, Ming ^a   Pederson, Larry ^a   Westendorf, Jennifer J ^a,b   Khosla, Sundeep ^a   Oursler, Merry Jo ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

AGING; OSTEOCLAST; SCLEROSTIN

Indexed keywords

NEUTRALIZING ANTIBODY; SCLEROSTIN;

AGED; AGING; ANIMAL CELL; ARTICLE; BONE MARROW CELL; BONE MINERALIZATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; GENETIC ANALYSIS; IN VITRO STUDY; ISOLATION PROCEDURE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STIMULATION; STROMA CELL;

AGING; ANIMALS; CALCIFICATION, PHYSIOLOGIC; CELLS, CULTURED; GENE EXPRESSION REGULATION; GLYCOPROTEINS; MICE; MICE, INBRED BALB C; OSTEOCLASTS; OSTEOGENESIS;

ANIMALIA; MURINAE; MUS;

EID: 84879159387     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24537     Document Type: Article

References (43)

1. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, Mandinova A, Raffoul W, Fiche M, Dotto GP, Brisken C,. 2006. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci USA 103: 3799-3804.
2. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle RJ, Boecker W,. 1999. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: A comparative study with CD44. Histopathology 34: 25-34.
3. Benhaj K, Akcali KC, Ozturk M,. 2006. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep 15: 701-707.
4. Donahue HJ, Zhou Z, Li Z, McCauley LK,. 1997. Age-related decreases in stimulatory G protein-coupled adenylate cyclase activity in osteoblastic cells. Am J Physiol 273: E776-E781.
5. Donahue SW, Jacobs CR, Donahue HJ,. 2001. Flow-induced calcium oscillations in rat osteoblasts are age, loading frequency, and shear stress dependent. Am J Physiol. Cell Physiol 281: C1635-C1641.
6. Genetos DC, Zhou Z, Li Z, Donahue HJ,. 2012. Age-related changes in gap junctional intercellular communication in osteoblastic cells. J Orthop Res 30: 1979-1984.
7. Hatsell S, Rowlands T, Hiremath M, Cowin P,. 2003. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8: 145-158.
8. Jonsson M, Borg A, Nilbert M, Andersson T,. 2000. Involvement of adenomatous polyposis coli (APC)/beta-catenin signalling in human breast cancer. Eur J Cancer 36: 242-248.
9. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, Keramopoulos A, Davaris PS, Pignatelli M,. 2001. Expression patterns of beta-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 27: 31-36.
10. Karst M, Gorny G, Galvin RJ, Oursler MJ,. 2004. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol 200: 99-106.
11. Khosla S,., 2001. Minireview: The OPG/RANKL/RANK system. Endocrinology 142: 5050-5055.
12. Khosla S, Westendorf JJ, Oursler MJ,. 2008. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 118: 421-428.
13. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Lowik CW, ten Dijke P,. 2010. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285: 41614-41626.
14. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C,. 2008. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860-869.
15. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C,. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588.
16. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D,. 2005. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280: 19883-19887.
17. Li Y, Hively WP, Varmus HE,. 2000. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19: 1002-1009.
18. Lips P, Courpron P, Meunier PJ,. 1978. Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age. Calcified Tissue Res 26: 13-17.
19. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM,. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15: 928-935.
20. Martin T, Gooi JH, Sims NA,. 2009. Molecular mechanisms in coupling of bone formation to resorption. Critic Rev Eukaryot Gene Expr 19: 73-88.
21. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ III, Khosla S,. 2011. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26: 373-379.
22. Olson DJ, Papkoff J,. 1994. Regulated expression of Wnt family members during proliferation of C57mg mammary cells. Cell Growth Differ 5: 197-206.
23. Padhi D, Jang G, Stouch B, Fang L, Posvar E,. 2011. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26.
24. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ,. 2008. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USAm 105: 20764-20769.
25. Qing H, Ardeshirpour L, Pajevic PD, Dusevich V, Jahn K, Kato S, Wysolmerski J, Bonewald LF,. 2012. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res 27: 1018-1029.
26. Rachner TD, Khosla S, Hofbauer LC,. 2011. Osteoporosis: Now and the future. Lancet 377: 1276-1287.
27. Roforth MM, Liu G, Khosla S, Monroe DG,. 2012. Examination of nuclear receptor expression in osteoblasts reveals Rorbeta as an important regulator of osteogenesis. J Bone Miner Res 27: 891-901.
28. Rubin CT, Bain SD, McLeod KJ,. 1992. Suppression of the osteogenic response in the aging skeleton. Calcified Tissue Int 50: 306-313.
29. Semenov M, Tamai K, He X,. 2005. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280: 26770-26775.
30. Subramaniam M, Gorny G, Johnsen SA, Monroe DG, Evans GL, Fraser DG, Rickard DJ, Rasmussen K, van Deursen JM, Turner RT, Oursler MJ, Spelsberg TC,. 2005. TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro. Mol Cell Biol 25: 1191-1199.
31. Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA,. 2004. Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation. Bone 35: 828-835.
32. Syed FA, Modder UI, Roforth M, Hensen I, Fraser DG, Peterson JM, Oursler MJ, Khosla S,. 2010. Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J Bone Miner Res 25: 2438-2446.
33. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Feng X, Van Hul W, Wan M, Cao X,. 2009. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15: 757-765.
34. Teitelbaum SL,. 2007. Osteoclasts: What do they do and how do they do it? Am J Pathol 170: 427-435.
35. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW,. 2004. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199: 805-814.
36. Wang H, Chen Q, Lee SH, Choi Y, Brad Johnson F, Pignolo RJ,. 2012. Impairment of osteoblast differentiation due to proliferation-independent telomere dysfunction in mouse models of accelerated aging. Aging Cell 11: 704-713.
37. Weisman LS, Emr SD, Wickner WT,. 1990. Mutants of Saccharomyces cerevisiae that block intervacuole vesicular traffic and vacuole division and segregation. Proc Natl Acad Sci USA 87: 1076-1080.
38. Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, Van Hul W,. 2003. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metabol 88: 5778-5783.
39. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA,. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276.
40. Wong GT, Gavin BJ, McMahon AP,. 1994. Differential transformation of mammary epithelial cells by Wnt genes. Mol Cell Biol 14: 6278-6286.
41. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL,. 2002. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 196: 145-153.
42. Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T, Crane J, Frassica F, Zhang L, Rodriguez JP, Xiaofeng J, Shoshana Y, Shouhong X, Argiris E, Mei W, Xu C,. 2012. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 18: 1095-1101.
43. Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA,. 2009. Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol 24: 385-398.